To carry out this study twelve cases were selected who were non-surgical candidates. The serial serum CEA concentrations were measured before ana after therpies (radiotherapy alone 5, chemotherapy alone 3 and both treatments in 4 patients). For the clinical evaluation, Type Ⅰ represents progressive rise, to levels greater than 2.5ng/㎖ (CEA), tumor progression and patient deterioration. Type Ⅱ represents progressive decline, initial level greater than 2.5 ng/㎖, and tumor response or clinical improvement.
The results were as follow:
1) 10 responses in 8 patients belong to group Ⅰ or Ⅱ, but excluded 6 responses in 5 patients from those groups whose initial CEA levels below the 2.5ng/㎖ (3) and dubious responses to determine (2 patients).
2) In radiotherapy group, 6 patients (67 percent) showed correlation between the curves of CEA response and clinical evaluation of disease activity. 4 patients (57 percent) of the chemotherapy group showed correlation between CEA ana clinical response.
3) In Type Ⅱ group, serum CEA concentrations were significantly decreased following each radiotheraphy or chemotherapy (p-value<0.005) but Type Ⅰ group (P-value>0.1).
4) These data intricate that serum CEA levels parallel, in general, clinical responses.
|